-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Early ivermectin treatment does not reduce symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online March 30 in the New England Journal of Medicine.
Gilmar Reis, MD, PhD, from the Roman Catholic University of Minas Gerais in Belo Horizante, Brazil, and colleagues conducted a double-blind randomized trial involving symptomatic SARS-CoV-2-positive adults people
The researchers found that 14.
There was one primary outcome event: COVID-19 hospitalization or worsening of COVID-19 in emergency department visits, defined as more than 6 hours of observation within 28 days after randomization; relative risk 0.
The authors wrote: "Based on the results obtained prior to our trial, the World Health Organization concluded that there is only very low-certainty evidence for ivermectin and therefore recommends that ivermectin should not be self-administered for the treatment of COVID-19 outside of a clinical trial setting.
But one of the authors of this article was disclosed to have financial ties to the pharmaceutical industry
